166 related articles for article (PubMed ID: 26118316)
1. Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children.
Fu R; Liu D; Cao Z; Zhu S; Li H; Su H; Zhang L; Xue F; Liu X; Zhang X; Cheng T; Yang R; Zhang L
Leukemia; 2016 Mar; 30(3):746-9. PubMed ID: 26118316
[No Abstract] [Full Text] [Related]
2. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
[No Abstract] [Full Text] [Related]
3. Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia.
Langabeer SE; Haslam K; McMahon C
Pediatr Blood Cancer; 2015 Jan; 62(1):175-6. PubMed ID: 25132652
[No Abstract] [Full Text] [Related]
4. JAK2, MPL, and CALR mutations in children with essential thrombocythemia.
Sekiya Y; Okuno Y; Muramatsu H; Ismael O; Kawashima N; Narita A; Wang X; Xu Y; Hama A; Fujisaki H; Imamura T; Hasegawa D; Kosaka Y; Sunami S; Ohtsuka Y; Ohga S; Takahashi Y; Kojima S; Shimada A
Int J Hematol; 2016 Aug; 104(2):266-7. PubMed ID: 27209416
[No Abstract] [Full Text] [Related]
5. MPL W515L mutation in pediatric essential thrombocythemia.
Farruggia P; D'Angelo P; La Rosa M; Scibetta N; Santangelo G; Lo Bello A; Duner E; Randi ML; Putti MC; Santoro A
Pediatr Blood Cancer; 2013 Aug; 60(8):E52-4. PubMed ID: 23441089
[TBL] [Abstract][Full Text] [Related]
6. Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
Kubuki Y; Shide K; Kameda T; Yamaji T; Sekine M; Kamiunten A; Akizuki K; Shimoda H; Tahira Y; Nakamura K; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Hashimoto K; Yamamoto S; Hasuike S; Hidaka T; Nagata K; Kitanaka A; Shimoda K
Ann Lab Med; 2017 Mar; 37(2):159-161. PubMed ID: 28029004
[No Abstract] [Full Text] [Related]
7. Essential thrombocythaemia.
Double G; Harrison C
Hematology; 2015 Mar; 20(2):119-20. PubMed ID: 25715049
[No Abstract] [Full Text] [Related]
8. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.
Nelson ND; Marcogliese A; Bergstrom K; Scheurer M; Mahoney D; Bertuch AA
Pediatr Blood Cancer; 2016 Aug; 63(8):1484-7. PubMed ID: 27100794
[TBL] [Abstract][Full Text] [Related]
10. CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia.
Shen H; Chao H; Ding Z; Feng Y; Cen J; Pan J; He J; Zhou M; Chen Z; Chen S
Leuk Lymphoma; 2015 Mar; 56(3):820-2. PubMed ID: 25005031
[No Abstract] [Full Text] [Related]
11. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing.
Angona A; Fernández-Rodríguez C; Alvarez-Larrán A; Camacho L; Longarón R; Torres E; Pairet S; Besses C; Bellosillo B
Blood Cancer J; 2016 Aug; 6(8):e463. PubMed ID: 27564461
[No Abstract] [Full Text] [Related]
13. Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: a single center prospective cohort experience.
Luque Paz D; Mansier O; Riou J; Conejero C; Roy L; Belkhodja C; Ugo V; Giraudier S
Haematologica; 2019 Apr; 104(4):e134-e137. PubMed ID: 30337359
[No Abstract] [Full Text] [Related]
14. CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients.
Bonifacio M; Montemezzi R; Parisi A; De Matteis G; Bertorelle R; Scaffidi L; Candiotto C; Lippi G; Zamò A; Chilosi M; Pizzolo G; Scarpa A; Krampera M
Ann Hematol; 2019 Oct; 98(10):2339-2346. PubMed ID: 31250082
[TBL] [Abstract][Full Text] [Related]
15. Capricious CALR mutated clones in myeloproliferative neoplasms.
Haslam K; Conneally E; Langabeer SE
Blood Cells Mol Dis; 2016 Mar; 57():110-1. PubMed ID: 26777583
[No Abstract] [Full Text] [Related]
16. Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia.
Mondet J; Park JH; Menard A; Marzac C; Carillo S; Pourcelot E; Girodon F; Cabagnols X; Lodé L; Socoro N; Chauvet M; Bulabois CE; Cony-Makhoul P; Corm S; Cahn JY; Mossuz P
Haematologica; 2015 May; 100(5):e176-8. PubMed ID: 25661444
[No Abstract] [Full Text] [Related]
17. Clinical effect of CALR allele burden in patients with essential thrombocythemia.
Bertozzi I; Biagetti G; Vezzaro T; Barzon I; Carraro M; Fabris F; Randi ML
Ann Hematol; 2022 Jun; 101(6):1345-1346. PubMed ID: 34743237
[No Abstract] [Full Text] [Related]
18. The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients.
Lau WW; Hannah R; Green AR; Göttgens B
Blood; 2015 Mar; 125(10):1679-81. PubMed ID: 25745188
[No Abstract] [Full Text] [Related]
19. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
[TBL] [Abstract][Full Text] [Related]
20. Searching for CALRity in myeloproliferative neoplasms.
Cook JR
Am J Clin Pathol; 2015 May; 143(5):617-9. PubMed ID: 25873492
[No Abstract] [Full Text] [Related]
[Next] [New Search]
